News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Doctor Who Blocked Thalidomide Dies
Kerry Grens | Aug 11, 2015
Frances Oldham Kelsey, a physician who halted use of a drug that caused birth defects in babies, has passed away at age 101.
Chronic Weed Use Shrinks Brain Region
Bob Grant | Nov 12, 2014
Long-term marijuana smokers have less gray matter in their orbitofrontal cortex than nonsmokers, but other brain circuits may compensate by increasing connectivity.
Epigenetic Cancer Therapy Clears Phase I
Tracy Vence | Apr 7, 2014
Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early-stage clinical trial.
Opinion: Translational Biotechnology
John D. Loike and Jennifer E. Miller | Feb 17, 2014
Regulators must consider both the promise and potential pitfalls of new technologies when determining whether to move them into clinical trials.
FDA Considers Easing Controls on Diabetes Drug
Dan Cossins | Jun 11, 2013
A panel of advisors says that the agency should loosen restrictions on the sale of a diabetes drug with a spotty clinical safety record.
How Safe Is Your Medicine Cabinet?
Megan Scudellari | May 1, 2013
After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.
Opinion: Regenerating Safely
Dan Orlando | Jan 21, 2013
Patient safety is paramount in regulating new stem cell treatments.
Fears over Fast-Tracking Drugs
Edyta Zielinska | Sep 10, 2012
Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.
Call for Diabetes Drug Ban
Sabrina Richards | Apr 30, 2012
A consumer advocacy group calls for a ban of a diabetes drug after evidence surfaces that it may increase the risk of cancer.
FDA Ups Recent Recalls
Bob Grant | Nov 9, 2011
The US regulatory agency recalled 54 percent more drugs from the second to third quarters of 2011.